Welcome to the latest issue of Pharmaceutical Technology Focus magazine

In the last few years, multimillion dollar revenues driven by popular demand, and even higher projections for the future have catapulted obesity drugs into the mainstream. In this month’s cover story, we take a look at what’s next in this field that is currently dominated by GLP-1 receptor agonists.

Also in this issue, an interview with a leading academic highlights why regulatory bodies need to evolve with our growing understanding of the obesity and diabetes drug development field, to ensure these drugs are accessible to all who can benefit from them.

In the broader pharmaceutical space, the high-profile acquisition of Catalent has been met with some backlash, which we investigate through a comment piece. Don’t miss other stories on how pharma is preparing for climate disasters, and the latest advances in addressing the opioid crisis. All this and the latest news and analysis on the pharmaceutical and biotech industry.

Manasi Vaidya, editor

Go to article: Home | Biotechs surf obesity drug wave to go beyond GLP-1RAsGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Trends & InsightGo to article: Bio Image SystemsGo to article: phasetwoGo to article: In DepthGo to article: Biotechs surf obesity drug wave to go beyond GLP-1RAsGo to article: The opioid crisis: Different delivery systems tackle treatment needs Go to article: Pharma readies for climate disasters amidst supply chain concernsGo to article: CRISPR pipeline accelerates after milestone Casgevy approvalGo to article: The future of cell and gene therapy manufacturingGo to article: Amgen showcases exciting potential in the obesity space at JPM24 Go to article: Q&A: Regulatory reform necessary to improve obesity drug accessGo to article: Novo to buy Catalent: The backlash beginsGo to article: Sponsored SupplementsGo to article: BEA TechnologiesGo to article: ListingsGo to article: EventsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue